NASDAQ: CV
Capsovision Inc Stock

$6.65+0.18 (+2.78%)
Updated Nov 17, 2026
CV Price
$6.65
Fair Value Price
N/A
Market Cap
$356.50M
52 Week Low
$4.50
52 Week High
$15.37
P/E
-15.47x
P/B
13.52x
P/S
23.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.92M
Earnings
-$29.25M
Gross Margin
49.7%
Operating Margin
-209.92%
Profit Margin
-210.1%
Debt to Equity
0.24
Operating Cash Flow
-$29M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CV Overview

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CV's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
CV
Ranked
#67 of 95

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$19.37A
$12.85A
$257.41A
View Top Medical Device Stocks

Be the first to know about important CV news, forecast changes, insider trades & much more!

CV News

Overview

Due Diligence Score

–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CV is poor value based on its book value relative to its share price (13.52x), compared to the US Medical Devices industry average (3.28x)
P/B vs Industry Valuation
CV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CV due diligence checks available for Premium users.

Valuation

CV price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-15.47x
Industry
25.21x
Market
39.5x

CV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
13.52x
Industry
3.28x
CV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CV's financial health

Profit margin

Revenue
$3.6M
Net Income
-$7.3M
Profit Margin
-205.7%
CV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$32.8M
Liabilities
$6.4M
Debt to equity
0.24
CV's short-term assets ($31.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CV's short-term assets ($31.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.0M
Investing
-$22.0k
Financing
$19.8M
CV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CV vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CVC$356.50M+2.78%-15.47x13.52x
BWAYC$365.58M-2.98%33.74x4.45x
VMDB$343.69M-0.87%22.68x2.29x
CERSB$383.71M+2.15%-63.33x5.07x
MASSC$390.46M+2.18%-14.67x2.61x

Capsovision Stock FAQ

What is Capsovision's quote symbol?

(NASDAQ: CV) Capsovision trades on the NASDAQ under the ticker symbol CV. Capsovision stock quotes can also be displayed as NASDAQ: CV.

If you're new to stock investing, here's how to buy Capsovision stock.

What is the 52 week high and low for Capsovision (NASDAQ: CV)?

(NASDAQ: CV) Capsovision's 52-week high was $15.37, and its 52-week low was $4.50. It is currently -56.73% from its 52-week high and 47.78% from its 52-week low.

How much is Capsovision stock worth today?

(NASDAQ: CV) Capsovision currently has 53,609,719 outstanding shares. With Capsovision stock trading at $6.65 per share, the total value of Capsovision stock (market capitalization) is $356.50M.

Capsovision stock was originally listed at a price of $3.50 in Jul 2, 2025. If you had invested in Capsovision stock at $3.50, your return over the last year would have been 90% (not including any dividends or dividend reinvestments).

How much is Capsovision's stock price per share?

(NASDAQ: CV) Capsovision stock price per share is $6.65 today (as of Nov 17, 2026).

What is Capsovision's Market Cap?

(NASDAQ: CV) Capsovision's market cap is $356.50M, as of Nov 18, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Capsovision's market cap is calculated by multiplying CV's current stock price of $6.65 by CV's total outstanding shares of 53,609,719.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.